Carfilzomib-d8

Carfilzomib-d8 is deuterium labeled Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.

Product Specifications

CAS Number

[1537187-53-3]

UNSPSC

12352005

Hazard Statement

H302+H312+H332-H315-H319

Target

Apoptosis; Autophagy; Isotope-Labeled Compounds; Proteasome

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Autophagy; Metabolic Enzyme/Protease; Others

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

98.93

Solubility

10 mM in DMSO|DMF : ≥ 15mg/mL|DMSO : ≥ 15mg/mL|Ethanol : ≥ 1mg/mL

Smiles

O=C([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@H](CC(C)C)NC([C@@H](NC(CN2C([2H])(C([2H])(OC([2H])(C2([2H])[2H])[2H])[2H])[2H])=O)CCC3=CC=CC=C3)=O)=O)=O)CC(C)C)[C@@]4(OC4)C

Molecular Formula

C40H49D8N5O7

Molecular Weight

727.96

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Dasmahapatra G, et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2011 Sep;10 (9) :1686-97.|[3]Kuhn DJ, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007 Nov 1;110 (9) :3281-90.